CD19 and mantle cell lymphoma: More recently, efforts in precision oncology have led to the advancement of new therapeutics for the treatment of refractory and resistant MCL, such as anti-CD19 chimeric antigen receptor (CAR) T cell therapy, anti-BCL2, or non-covalent Bruton’s tyrosine kinase (BTK) inhibitors (6–11).